Eli Lilly and Company (India) has raised alarms over counterfeit versions of Mounjaro (tirzepatide) following a successful operation by the Haryana State-FDA in Gurugram, where fake products were seized. These counterfeit drugs pose significant health risks, as they may contain incorrect dosages or harmful substances, including insulin, which can lead to severe hypoglycemia. Winselow Tucker, President of Eli Lilly (India), highlighted the company's commitment to patient safety and urged consumers to purchase medications only through authorized channels. Patients should be cautious of red flags such as tampered packaging, missing information, and unauthorized sources when obtaining medications. A valid prescription is essential to ensure that the medication is appropriate for the patient's health needs. The ongoing efforts by regulatory authorities in Haryana aim to combat counterfeit drugs, but individuals must also remain vigilant to protect their health.